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Abstract
Background: Recent work has suggested that the ovarian steroid 17β -estradiol, at physiological
concentrations, may exert protective effects in neurodegenerative disorders such as Alzheimer's
disease, Parkinson's disease and acute ischemic stroke. While physiological concentrations of
estrogen have consistently been shown to be protective in vivo, direct protection upon purified
neurons is controversial, with many investigators unable to show a direct protection in highly
purified primary neuronal cultures. These findings suggest that while direct protection may occur
in some instances, an alternative or parallel pathway for protection may exist which could involve
another cell type in the brain.
Presentation of the Hypothesis: A hypothetical indirect protective mechanism is proposed
whereby physiological levels of estrogen stimulate the release of astrocyte-derived neuroprotective
factors, which aid in the protection of neurons from cell death. This hypothesis is attractive as it
provides a potential mechanism for protection of estrogen receptor (ER)-negative neurons through
an astrocyte intermediate. It is envisioned that the indirect pathway could act in concert with the
direct pathway to achieve a more widespread global protection of both ER+ and ER- neurons.
Testing the hypothesis: We hypothesize that targeted deletion of estrogen receptors in
astrocytes will significantly attenuate the neuroprotective effects of estrogen.
Implications of the hypothesis: If true, the hypothesis would significantly advance our
understanding of endocrine-glia-neuron interactions. It may also help explain, at least in part, the
reported beneficial effects of estrogen in neurodegenerative disorders. Finally, it also sets the stage
for potential extension of the hypothetical mechanism to other important estrogen actions in the
brain such as neurotropism, neurosecretion, and synaptic plasticity.
Background
Over the past decade, evidence has emerged in support of
a neuroprotective role for the most potent estrogen in hu-
man and rodents, 17β -estradiol. The issue of estrogen pro-
tection is important, as there is a dramatic age-related
decline in estrogen levels in women, such that postmeno-
pausal women have estrogen levels that are approximately
1% of that observed in pre-menopausal women. Coincid-
ing with the estrogen depleted state that occurs at meno-
pause, the risk for stroke and other neurodegenerative
diseases increases dramatically. While this correlative rela-
tionship may be more coincidental than causative, a large
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number of animal studies have suggested that a neuropro-
tective role does exist for estrogen; a finding that has pro-
pelled interest in determining the effectiveness of estrogen
in the prevention of neurodegenerative and cerebrovascu-
lar disease in humans [1–9]. Additional research has sug-
gested a beneficial role for estrogen in Alzheimer's disease
and Parkinson's disease based on the results of both hu-
man and animal studies [10–13].
In support of a possible neuroprotective role for estrogen,
it has been shown that intact adult female rats sustain
lower mortality and less neuronal damage as compared to
age-matched male rats following middle cerebral artery
occlusion [14]. That an ovarian factor is involved in the
protection was suggested by the finding that ovariectomy
(OVX) eliminates the endogenous protective effect ob-
served in females following cerebral ischemia [14]. Addi-
tionally, serum estradiol levels have been shown to be
inversely correlated with ischemic stroke damage in female
rats [15]. Finally, a large number of studies have shown
that estrogen replacement to ovariectomized animals re-
instates protection of the brain to a level similar to that
observed in intact animals [3,4],[6–8],[16–20]. With re-
gards to brain regions protected by estrogen, most studies
show that the cerebral cortex is most strongly protected,
followed by the striatum [1]. Estrogen has also been
shown to strongly protect the hippocampus region in a
model of transient global ischemia, which specifically tar-
gets the hippocampal CA1 region [20].
With respect to the mechanism of action of estrogen pro-
tection, several studies have reported that a 24-hour pre-
treatment with physiological doses of estrogen is
necessary to reduce infarct volume following cerebral
ischemia in OVX female animals [4,7,16]. Pretreatment
with physiological doses of estrogen for less than 24 h or
at the time of middle cerebral artery occlusion fails to re-
duce brain injury [4]. Additional work has shown that es-
trogen protection is independent of effects on cerebral
blood flow [4,9,17,19]. These findings have been inter-
preted to mean that protection by physiological doses of
estrogen most likely occurs directly at the level of the
brain rather than on the vasculature, and that the mecha-
nism involves genomic activation of nuclear estrogen re-
ceptors and subsequent induction of neuroprotective
factors [16,18,21,22]. In support of a critical role for estro-
gen receptors in estrogen protection, treatment with
ICI182,780, a potent estrogen receptor antagonist, has
been shown to significantly exacerbate infarct volume fol-
lowing cerebral ischemia in intact female rats [23].
To further elucidate the mechanism of estrogen-mediated
neuroprotection, many researchers have attempted to use
primary neuronal cultures and immortalized neuronal
cell lines. The results of these studies have produced con-
flicting results. Although there are reports that physiolog-
ically relevant concentrations of estrogen protect purified
neurons directly in vitro [24–27], a number of investiga-
tors have been unable to confirm a direct neuroprotection
with physiological doses of estrogen [28–32]. These find-
ings suggest that while direct protection may occur in
some instances, an alternative or parallel pathway for pro-
tection may exist which could involve another non-neuro-
nal cell type in the brain. This hypothesis is supported by
the observation that physiological doses of estrogen are
neuroprotective in rat organotypic cortical explant cul-
tures, which have an intact cellular and tissue architecture
and which contain multiple cell types [33].
Of the non-neuronal cell types in the brain, the astrocyte
has perhaps the greatest potential for possible involve-
ment in the mediation of estrogen neuroprotective effects.
Astrocytes are the most abundant type of glial cell in the
brain and are located in juxtaposition to neurons, out-
numbering them by a 10:1 ratio in some regions of the
brain. Astrocytes are well-known to maintain homeostasis
in the brain, and have been implicated in the process of
synaptic remodeling. Astrocytes also appear to have a crit-
ical role in protection/survival of neurons in the brain, as
ablation of astrocytes in vivo results in a significant de-
crease in neuronal survival [34]. The mechanism of astro-
cyte-mediated neuroprotection is an area of intense
investigation, with several possible mediators of this effect
implicated [1,34–39]. Recent work by our laboratory has
demonstrated the presence of an estrogen-astrocyte-TGF-
β 1 pathway, which may have implications in mediating
the neuroprotective effects of estrogen in the brain [38].
That astrocyte-derived TGF-β  can protect neurons has
been demonstrated by Bruno et al. [39], who demonstrat-
ed that metabotropic glutamate agonists protect against
neuronal injury by enhancing astrocyte-derived release of
TGF-β 1. Interestingly, Garcia-Segura and coworkers have
also demonstrated that estrogen can enhance levels of an-
other neuroprotective growth factor in brain astrocytes,
insulin-like growth factor-1 (IGF-1) [40].
In support of astrocytes being a target for and mediator of
estrogen action in the brain, estrogen has been demon-
strated to increase glial cell proliferation and enhance ex-
pression of the astrocyte specific marker, glial fibrillary
acidic protein (GFAP) [41]. Furthermore, colocalization
of estrogen receptors in astrocytes in a variety of brain re-
gions has been confirmed immunocytochemically in
brain sections derived from the guinea pig, rat, and hu-
man [42–47]. Estrogen receptor-α  and β  have also been
demonstrated in rat cortical, hippocampal and hypotha-
lamic astrocytes in vitro by a number of investigators
[38,48–50]. Of significant interest is the finding that fol-
lowing fornix transection in the primate, an astrocyte-spe-
cific increase in ER-α  expression occurs, suggesting thatBMC Neuroscience 2002, 3 http://www.biomedcentral.com/1471-2202/3/6
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astrocytes may be especially sensitive to estrogen effects
after an injury [51]. In a parallel fashion, ER-α  transcript
has been reported to increase in the cerebral cortex follow-
ing acute ischemic stroke injury in rats [16]. Taken as a
whole, these studies indicate astrocytes may be targets for
estrogen action in vivo, and support the concept that astro-
cytes could mediate, at least in part, the neuroprotective
and neurotrophic effects of physiological estrogen in the
brain.
Presentation of the hypothesis
It is hypothesized that estrogen-induced neuroprotection
achieved with physiological doses of estrogen involves, at
least in part, mediation by astrocytes, which is in addition
to a possible direct neuroprotection pathway. This postu-
lated parallel pathway of indirect and direct protection is
attractive as it may explain how estrogen can achieve
widespread protection of the cerebral cortex, striatum and
hippocampus despite the fact that the estrogen receptor is
not globally expressed in all neurons in these regions.
Thus, in our hypothetical model, the ability of physiolog-
ical levels of estrogen to achieve widespread protection in
the brain is due to a postulated direct protection on a sub-
population of ER-positive neurons, coupled with a poten-
tial indirect protection of ER-negative neurons via an
astrocyte intermediacy involving release of astrocyte-de-
rived neuroprotective growth factors.
Testing of the hypothesis
Targeted deletion of astrocytic estrogen receptors (ER-α
and/or ER-β ) is expected to significantly attenuate the
neuroprotection observed following estrogen treatment
in OVX female rodents undergoing ischemia.
Implications of the hypothesis
We propose that astrocytes play a role in mediating the
neuroprotective effects of estrogen on the brain. Such a
hypothetical pathway, if proven true, would go a long way
to explain how estrogen may exert its beneficial effects in
such important neurodegenerative disorders as Alzheim-
er's disease, Parkinson's disease and acute ischemic stroke,
and may help explain how estrogen can exert widespread
neuronal protection despite a limited neuronal expression
pattern of its receptors.
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